ACADIA Pharmaceuticals Inc (ACAD.OQ)
13.27USD
17 May 2013
$0.26 (+2.00%)
$13.01
$13.04
$13.59
$12.99
1,320,310
864,366
$13.92
$1.30
ACAD.OQ
About
Overall
| Beta: | 2.85 |
| Market Cap (Mil.): | $1,151.88 |
| Shares Outstanding (Mil.): | 86.80 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ACAD.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 53.78 | 35.83 |
| EPS (TTM): | -0.38 | -- | -- |
| ROI: | -32.43 | 1.00 | 18.72 |
| ROE: | -38.49 | 2.10 | 19.54 |
Acadia says data from Parkinson's trial enough to file for approval
- Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, and that it would not need to conduct an additional trial as planned earlier.
BRIEF-ACADIA Pharma up in premarket after phase III pimavanserin study data
NEW YORK, March 21 - ACADIA Pharmaceuticals Inc : * Pharma up 6.5 percent to $7.08 in premarket after phase III pimavanserin study data
UPDATE 1-Acadia antipsychotic for Parkinson's succeeds in trial
* Achieves antipsychotic effect without loss of motor function
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $28.96 | -0.29 |
| Johnson & Johnson (JNJ.N) | $88.09 | +0.64 |
| AstraZeneca plc (AZN.L) | 3,383.00p | -6.50 |
| Eli Lilly & Co. (LLY.N) | $55.90 | -0.04 |
| Bristol Myers Squibb Co. (BMY.N) | $43.30 | +0.53 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
| Allergan, Inc. (AGN.N) | $101.41 | +0.99 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
